There are currently 403 clinical trials in Scottsdale, Arizona looking for participants to engage in research studies. Trials are conducted at various facilities, including Mayo Clinic in Arizona, Mayo Cliinic - Scottsdale, Mayo Clinic and Mayo Clinic Arizona. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa (HS)
NCT05620836
Recruiting
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Investigative Site US240, Scottsdale, Arizona +1 locations
Conditions: Hidradenitis Suppurativa (HS)
Register for Updates
Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS
NCT05918861
Recruiting
This is a placebo-controlled, randomized, double-blind, parallel group, phase 3 multicenter study in subjects recently hospitalized for ACS and with the appropriate genetic profile. Subjects will provide informed consent before any study-specific procedures are performed. A separate informed consent will be allowed for an initial pre-screening genetic testing. Subjects meeting the AA genotype will then consent to the full study and confirmatory genetic testing as required. Subject enrollment may... Read More
Gender:
All
Ages:
45 years and above
Trial Updated:
06/21/2024
Locations: Research Site, Scottsdale, Arizona
Conditions: Acute Coronary Syndrome
Register for Updates
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926
Recruiting
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Honor Health Research Institute, Scottsdale, Arizona
Conditions: Melanoma Stage IV, Solid Tumor
Register for Updates
A Feasibility Trial to Investigate the Safety and Between-group Effect Size of STIMULAN VG and Standard of Care (SoC) in Participants With Diabetic Foot Osteomyelitis
NCT05539963
Recruiting
The purpose of this trial is to evaluate the safety and between-group effect size of STIMULAN VG compared to SoC treatment in patients with diabetic foot osteomyelitis (DFO).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Perseverance Research Center, LLC, Scottsdale, Arizona
Conditions: Diabetic Foot Osteomyelitis
Register for Updates
A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
NCT05936151
Recruiting
The main purpose of this study is to investigate the effect of retatrutide on renal function in participants with overweight or obesity and chronic kidney disease (CKD), with or without Type 2 Diabetes (T2D). The study will lasts around 31 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Headlands Research - Scottsdale, Scottsdale, Arizona
Conditions: Overweight or Obesity, CKD, Type 2 Diabetes
Register for Updates
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
NCT02194738
Recruiting
This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
Register for Updates
Testing Obeticholic Acid for Familial Adenomatous Polyposis
NCT05223036
Recruiting
This phase IIa trial investigates if giving obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in patients with familial adenomatous polyposis (FAP). FAP is a rare gene defect that increases the risk of developing cancer of the intestines and colon. OCA is a drug similar to a bile acid the body makes. It is fluid made and released by the liver. OCA binds to a receptor in the intestine that is believed to have a positive effect on preve... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Attenuated Familial Adenomatous Polyposis, Colorectal Carcinoma, Familial Adenomatous Polyposis, Duodenal Carcinoma
Register for Updates
A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis
NCT05798520
Recruiting
The primary objectives are to investigate the safety and tolerability of BIIB091 monotherapy in participants with relapsing multiple sclerosis (RMS) (Part 1), and to evaluate the effects of BIIB091 combination therapy with Diroximel Fumarate (DRF) compared with the DRF monotherapy arm, on the key Magnetic Resonance Imaging (MRI) measure of active Central Nervous System (CNS) inflammation (Part 2). The secondary objectives are to evaluate the effects of BIIB091 monotherapy on the MRI measures of... Read More
Gender:
All
Ages:
Between 18 years and 55 years
Trial Updated:
06/21/2024
Locations: HonorHealth Neurology, Scottsdale, Arizona
Conditions: Relapsing Forms of Multiple Sclerosis
Register for Updates
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486
Recruiting
The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the disability progression and the safety up to approximately 51 months administration of study intervention compared to placebo in male and female participants with nrSPMS (aged 18 to 60 years at the time of enrollment). People diagnosed with nrSPMS are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion crite... Read More
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
06/21/2024
Locations: Perseverance Research Center Site Number : 8400138, Scottsdale, Arizona +1 locations
Conditions: Multiple Sclerosis
Register for Updates
Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies
NCT02672917
Recruiting
Phase 1 Safety and Tolerability Study in Subjects with Pancreatic Cancer or Other CA19-9 Positive Malignancies.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/20/2024
Locations: HonorHealth Research Institute, Scottsdale, Arizona
Conditions: Pancreatic Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOG-AD)
NCT05063162
Recruiting
The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOG-AD).
Gender:
All
Ages:
Between 18 years and 89 years
Trial Updated:
06/20/2024
Locations: Mog001 50297, Scottsdale, Arizona
Conditions: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOG-AD)
Register for Updates
A Study to Evaluate Efficacy and Safety of SAR441566 in Adults With Plaque Psoriasis
NCT06073119
Recruiting
This is a Phase 2, international, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, 12-week study. It is designed to assess the therapeutic dose, efficacy, and safety of treatment with SAR441566 in male and female adults with moderate to severe plaque psoriasis. Study details include a screening period (4 weeks and not less than 11 days before Day 1), a treatment period (12 weeks ± 3 days) and a post-treatment period (safety follow-up) (2 weeks ± 3 days). The total number... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/20/2024
Locations: Scottsdale Clinical Trials Site Number : 8400025, Scottsdale, Arizona
Conditions: Psoriasis
Register for Updates